Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | PHASE2 | RECRUITING | 47 | — | — | Feb 2, 2023 | Apr 12, 2027 | Jan 23, 2026 | 4 | United States |
The primary endpoint is the efficacy of treatment via assessment of 6 month rPFS defined by RECIST version 1.1 for soft tissue and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases. rPFS is defined as the duration of time from the first day of the start of study treatment to time of radiographic progression or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Experimental Group | EXPERIMENTAL | 40 mg of cabozantinib taken orally every day (days 1-28) of a 28 day cycle 480 mg of nivolumab given intravenously on the first day (day 1) of each 28 day cycle |
| Name | Type | Description |
|---|---|---|
| Cabozantinib | DRUG | 40 mg taken orally |
| Nivolumab | DRUG | 480 mg by infusion |
Inclusion Criteria: Subjects must meet all of the following applicable inclusion criteria to participate in this study: * Willing and able to provide, or have a legally authorized representative provide, written informed consent and HIPAA authorization for the release of personal health informatio...